Vanguard Asset Management
AMLX icon

Vanguard Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Vanguard Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02M Buy
56,948
+13,665
+32% +$211K ﹤0.01% 1868
2026
Q1 		$602K Buy
+43,283
New +$609K ﹤0.01% 2004

Other funds holding AMLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Asset Management's AMLX Position: Q2 2026 in Review

Vanguard Asset Management increased its Amylyx Pharmaceuticals (AMLX) stake by 32% in Q2 2026, buying an estimated $211K and bringing the position to 56,948 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1868.

Vanguard Asset Management first reported a position in AMLX in Q1 2026 and has held it in 2 quarters since. 182 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Vanguard Asset Management held 56,948 shares of Amylyx Pharmaceuticals worth $1.02M as of Q2 2026.
  • Vanguard Asset Management bought 13,665 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $211K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #1868 holding.
  • Vanguard Asset Management first reported a position in Amylyx Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 182 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.